The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C–mutated advanced pancreatic cancer.
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Michael Charles Burns
Employment - Abbvie
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Exelixis; Ipsen
Speakers' Bureau - Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Mary Frances Mulcahy
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - BTG
 
Al Bowen Benson
Consulting or Advisory Role - Abbvie; Apexigen; Array BioPharma; Artemida Pharma; Boston Scientific; Bristol-Myers Squibb; HalioDx; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Natera; Pfizer; Samsung Bioepis; Therabionic; Xencor
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITM Solucin (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)